A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases

Drug-related adverse events or adverse drug reactions (ADRs) are currently partially or substantially under-reported. ADR reporting systems need to expand their focus to include sex- and gender-related factors in order to understand, prevent, or reduce the occurrence of ADRs in all people, particula...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Andreea C. Brabete, Lorraine Greaves, Mira Maximos, Ella Huber, Alice Li, Mê-Linh Lê
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Subjects:	adverse drug reactions sex gender SGBA+ lifecycle management of drugs pharmacovigilance
Online Access:	https://www.mdpi.com/1424-8247/15/3/298

Similar Items

Training in the implementation of sex and gender research policies: an evaluation of publicly available online courses
by: Annika Gompers, et al.
Published: (2024-04-01)

Sex and gender differences and pharmacovigilance: a knot still to be untied
by: Liberata Sportiello, et al.
Published: (2024-04-01)

Pharmacovigilance: Scope for a dermatologist
by: Bhanu Prakash, et al.
Published: (2011-01-01)

Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting
by: Hadi MA, et al.
Published: (2017-03-01)

Pharmacovigilance: Empowering healthcare professionals
by: Mugoša Snežana S., et al.
Published: (2015-01-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
by: E. N. Tkhoseva, et al.
Published: (2022-06-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
by: Yu. V. Muravyev
Published: (2017-09-01)

Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program
by: Tinashe Mudzviti, et al.
Published: (2012-11-01)

Perspective of undergraduate health-care students on adverse drug reaction and pharmacovigilance
by: Ahmed Atia, et al.
Published: (2023-01-01)

Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database
by: Yang Rui, et al.
Published: (2025-08-01)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
by: Louis Létinier, et al.
Published: (2021-03-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Investigation of the characteristics of medication errors and adverse drug reactions using pharmacovigilance data in China
by: Xiaofang Tan, et al.
Published: (2020-10-01)

Adverse drug reaction reporting for more than a decade: The need for pharmacovigilance policy implementation in Turkey
by: Zakir Khan, M.Phil, et al.
Published: (2022-04-01)

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)

Analysis of adverse drug reactions reported to national pharmacovigilance center of Bhutan
by: Pelden Chejor, et al.
Published: (2021-06-01)

Role of Pharmacovigilance in Drug Safety Monitoring
by: Anju E. Paul, et al.
Published: (2025-07-01)

Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study
by: Jingying Wu, et al.
Published: (2024-09-01)

Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database
by: Alexandre O. Gérard, et al.
Published: (2025-08-01)

Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait
by: Fatemah M. Alsaleh, et al.
Published: (2017-09-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
by: S. K. Zyryanov, et al.
Published: (2020-05-01)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
by: Stefania Chiappini, et al.
Published: (2022-05-01)

SIGNIFICANCE OF PHARMACOVIGILANCE AND ITS CLINICAL IMPLICATIONS
by: Susanta Kumar Bandyopadhyay, et al.
Published: (2016-12-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024
by: Siyu Liu, et al.
Published: (2025-06-01)

A pharmacovigilance approach for assessing the occurrence of suicide-related events induced by antiepileptic drugs using the Japanese adverse drug event report database
by: Takenao Koseki, et al.
Published: (2023-01-01)

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database
by: Wangyu Ye, et al.
Published: (2024-09-01)

Pharmacovigilance study of spontaneous adverse drug reaction in a tertiary care centre
by: Wazid Ali, et al.
Published: (2022-01-01)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
by: Xiaogan Wang, et al.
Published: (2024-09-01)

Pharmacovigilance of Severe Cutaneous Adverse Drug Reactions
by: Kriteeka Saini, et al.
Published: (2022-01-01)

Current status and future prospects of pharmacovigilance in Pakistan
by: Rabia Hussain, et al.
Published: (2019-12-01)

A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023
by: Yitong Wang, et al.
Published: (2025-05-01)

Review of the monograph by Kolbin A. S., Zyryanov S. K., Belousov D. Yu. "Pharmacovigilance" 2025
by: V. I. Petrov
Published: (2025-01-01)

Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system
by: Jianing Bi, et al.
Published: (2025-10-01)

Adverse drug reactions of macrolide therapy: analysis of spontaneous reports according to the Pharmacovigilance system
by: Skryabina A.A., et al.
Published: (2023-03-01)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
by: Hong Pan, et al.
Published: (2024-12-01)

Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database
by: Jung-Yoon Choi, et al.
Published: (2021-05-01)